Gilead's executive VP of worldwide commercial operations is unexpectedly retiring, at a time when the company is facing challenges across its infectious-disease and oncology portfolios. The news comes just two weeks after Gilead warned investors that sales in its hepatitis C franchise would fall short of expectations.Original Article
Gilead loses its head of commercial operations as it takes on daunting sales challenges
